We are so pleased that 5,000 Australian cancer patients have accessed genomic technology via our Molecular Screening and Therapeutics (MoST) study.

More than 80% of patients screened since 2016 were matched to a MoST study, and to date, 700 patients have received 789 matched therapies – giving hope to the rare and advanced cancer population where there has been none.

We’re proud to celebrate this important milestone but are reminded that the work we do is so much more than just the numbers. Thanks to the dedication of researchers and clinicians, the impact that this program on the lives of patients and their families is immeasurable.